Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures


LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the start of a targeted commercial launch for the

Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022:
Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022


Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022


Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that two abstracts featuring non-clinical data from studies evaluating FAP-2286 and Rubraca and a Trial-in-Progress poster detailing the Phase

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields


Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held

DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
DGAP-News: Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb
DGAP-News: Evotec erreicht Programmauswahl in Neurologie-Kooperation mit Bristol Myers Squibb
Quidel Announces Preliminary Revenue for First Quarter 2022
Quidel Announces Preliminary Revenue for First Quarter 2022


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital


Regulatory News:



Nanobiotix (Paris:NANO) (NASDAQ:NBTX):



Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.P
Website

Chemed To Report First-Quarter 2022 Earnings April 26, Related Conference Call To Be Held On April 27:
Chemed To Report First-Quarter 2022 Earnings April 26, Related Conference Call To Be Held On April 27


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2022, on Tuesday, April 26, 2022, following the close of trading on the

Dexcom Publishes Annual Sustainability Report: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Publishes Annual Sustainability Report


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its third annual Sustainability Report. This report

Charles River Laboratories Publishes 2021 Corporate Citizenship Report: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Publishes 2021 Corporate Citizenship Report


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2021 Corporate Citizenship Report. The 2021 report demonstrates Charles River’s priorities and

DGAP-HV: STRATEC SE: Bekanntmachung der Einberufung zur Hauptversammlung am 20.05.2022 in Virtuelle Hauptversammlung mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: STRATEC SE: Bekanntmachung der Einberufung zur Hauptversammlung am 20.05.2022 in Virtuelle Hauptversammlung mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: STRATEC SE: Bekanntmachung der Einberufung zur Hauptversammlung am 20.05.2022 in Virtuelle Hauptversammlung mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidateshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates


Pfizer Inc. (NYSE: PFE) and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage

ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury


Regulatory News:



ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today

DGAP-News: Biotest AG: Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement
DGAP-News: Biotest AG: Biotest submits marketing authorisation application for IgG Next Generation and signed first licensing agreement
DGAP-News: Biotest AG: Biotest reicht Zulassungsantrag für IgG Next Generation ein und unterzeichnet ersten Lizenzvertrag: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest reicht Zulassungsantrag für IgG Next Generation ein und unterzeichnet ersten Lizenzvertrag
DGAP-News: Biotest AG: Biotest reicht Zulassungsantrag für IgG Next Generation ein und unterzeichnet ersten Lizenzvertrag
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders on 28 April 2022http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders on 28 April 2022
AEVIS VICTORIA SA - Ordinary General Meeting of Shareholders on 28 April 2022
AEVIS VICTORIA SA - Ordentliche Generalversammlung vom 28. April 2022http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA - Ordentliche Generalversammlung vom 28. April 2022
AEVIS VICTORIA SA - Ordentliche Generalversammlung vom 28. April 2022
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
DGAP-News: Gerresheimer AG: Gerresheimer hebt nach starkem 1. Quartal Umsatzprognose für 2022 auf zweistelliges Wachstum an
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second

AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022
AMN Healthcare to Hold First Quarter 2022 Earnings Conference Call on Thursday, May 5, 2022


AMN Healthcare Services, Inc. (NYSE: AMN) has scheduled a conference call to discuss its first quarter 2022 financial results and second quarter 2022 outlook on Thursday, May 5, 2022 at 5:00 p.m

New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+


According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been

Charles River Laboratories Acquires Explora BioLabs: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Acquires Explora BioLabs


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Explora BioLabs Holdings, Inc., a premier provider of contract vivarium research services.



Based in

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg
Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the